RU2003121240A - Препараты стероидного гормона и способы их получения - Google Patents
Препараты стероидного гормона и способы их получения Download PDFInfo
- Publication number
- RU2003121240A RU2003121240A RU2003121240/15A RU2003121240A RU2003121240A RU 2003121240 A RU2003121240 A RU 2003121240A RU 2003121240/15 A RU2003121240/15 A RU 2003121240/15A RU 2003121240 A RU2003121240 A RU 2003121240A RU 2003121240 A RU2003121240 A RU 2003121240A
- Authority
- RU
- Russia
- Prior art keywords
- steroid hormone
- carrier
- hormone
- mixture
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (17)
1. Препарат стероидного гормона, обладающий улучшенными параметрами растворения и скорости высвобождения, указанный препарат находится, по существу, в некристаллической форме в смеси с носителем, указанный носитель, стабилизирующий указанный гормон, находится, по существу, в некристаллической форме.
2. Препарат стероидного гормона по п.1, где основной носитель выбран из группы, состоящей из декстрозы, фруктозы, сорбита, ксилита, сахарозы, лактозы, маннита, декстрата, целлюлозы, крахмала и их смесей.
3. Препарат стероидного гормона по п.1, где стероидным гормоном является, по крайней мере, один из прогестина и эстрогена.
4. Препарат стероидного гормона по п.3, где стероидным гормоном является прогестин, выбранный из группы, состоящей из норгестимата, норгестрела, левоноргестрела, норэтиндрона и десогестрела.
5. Препарат стероидного гормона по п.4, где стероидным гормоном является норгестимат и носителем является лактоза.
6. Препарат стероидного гормона по п.3, где препаратом является один из пероральных контрацептивных препаратов и препаратов для заместительной гормональной терапии.
7. Препарат стероидного гормона по п.6, где препаратом является пероральный контрацептивный препарат, содержащий приблизительно от 10 до 50 мкг эстрогена и/или приблизительно от 50 до 300 мкг прогестина.
8. Препарат стероидного гормона по п.7, где прогестином является норгестимат и носителем является лактоза.
9. Способ получения препарата стероидного гормона, обладающего улучшенными параметрами растворения и скорости высвобождения, включающий в себя стадии:
- приготовления смеси, содержащей, по крайней мере, один стероидный гормон и, по крайней мере, один носитель;
- обработки указанной смеси путем приложения достаточного количества механической энергии с целью получения порошковой смеси носитель/гормон, где гормон стабилизирован указанным носителем, в основном, в некристаллической форме; и
- получения указанного препарата из порошковой смеси.
10. Способ по п.9, где смесь обрабатывают путем приложения механической энергии, составляющей, по крайней мере, 0,1 лошадиной силы-мин/кг, с образованием порошковой смеси.
11. Способ по п.9, где стадия обработки смеси путем приложения механической энергии отличается, кроме того, тем, что смесь подвергают смешиванию при высоком уровне энергии.
12. Способ по п.9, где смесь содержит гормон/носитель при соотношении приблизительно от 1/1 до 1/10.
13. Способ по п.9, где основной носитель выбран из группы, состоящей из декстрозы, фруктозы, сорбита, ксилита, сахарозы, лактозы, маннита, декстрата, целлюлозы, крахмала и их смесей.
14. Способ по п.9, где стероидным гормоном является, по крайней мере, один из прогестина и эстрогена.
15. Способ по п.14, где стероидным гормоном является прогестин, выбранный из группы, состоящей из норгестимата, норгестрела, левоноргестрела, норэтиндрона и десогестрела.
16. Способ по п.15, где стероидным гормоном является норгестимат и носителем является лактоза.
17. Способ по п.9, где стадия получения смеси включает в себя стадии:
- приготовления раствора гормона в подходящем растворителе;
- смешивания раствора с носителем с получением однородной смеси; и
- удаления растворителя.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25566900P | 2000-12-14 | 2000-12-14 | |
| US60/255,669 | 2000-12-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003121240A true RU2003121240A (ru) | 2005-02-10 |
| RU2286155C2 RU2286155C2 (ru) | 2006-10-27 |
Family
ID=22969374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003121240/15A RU2286155C2 (ru) | 2000-12-14 | 2001-12-13 | Препараты стероидного гормона и способы их получения |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US7867990B2 (ru) |
| EP (2) | EP1591121B1 (ru) |
| KR (1) | KR100899032B1 (ru) |
| CN (1) | CN1290507C (ru) |
| AT (2) | ATE307591T1 (ru) |
| AU (2) | AU2002227421B2 (ru) |
| BG (1) | BG66178B1 (ru) |
| BR (1) | BRPI0116793B8 (ru) |
| CA (1) | CA2431521E (ru) |
| CR (1) | CR7022A (ru) |
| CY (1) | CY1109404T1 (ru) |
| CZ (1) | CZ306435B6 (ru) |
| DE (2) | DE60139087D1 (ru) |
| DK (2) | DK1361881T3 (ru) |
| EC (1) | ECSP034654A (ru) |
| EE (1) | EE05358B1 (ru) |
| ES (2) | ES2327538T3 (ru) |
| HK (2) | HK1057174A1 (ru) |
| HU (1) | HU230400B1 (ru) |
| IL (2) | IL156423A0 (ru) |
| ME (1) | ME00339B (ru) |
| MX (1) | MXPA03005339A (ru) |
| NO (2) | NO334341B1 (ru) |
| NZ (1) | NZ526517A (ru) |
| PT (1) | PT1591121E (ru) |
| RS (1) | RS50414B (ru) |
| RU (1) | RU2286155C2 (ru) |
| SK (1) | SK288222B6 (ru) |
| UA (1) | UA77404C2 (ru) |
| WO (1) | WO2002047693A2 (ru) |
| ZA (1) | ZA200305342B (ru) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| ES2327538T3 (es) * | 2000-12-14 | 2009-10-30 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Proceso para preparar productos de hormona esteroidea que comprenden un agente estabilizante en forma no cristalina. |
| US7858607B2 (en) * | 2003-03-14 | 2010-12-28 | Mamchur Stephen A | System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer |
| EP1844765B1 (en) * | 2003-06-13 | 2015-01-21 | Skendi Finance, Ltd. | Slow release estradiol-progesterone formulation |
| US8101244B2 (en) | 2004-06-09 | 2012-01-24 | Smithkline Beecham Corporation | Apparatus and method for producing or processing a product or sample |
| TWI547431B (zh) | 2004-06-09 | 2016-09-01 | 史密斯克萊美占公司 | 生產藥物之裝置及方法 |
| EP1625849A1 (en) * | 2004-08-09 | 2006-02-15 | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. | Pharmaceutical composition comprising drospirenone and ethynylestradiol |
| US8486926B2 (en) * | 2006-11-17 | 2013-07-16 | Harbor Therapeutics, Inc. | Steroid tetrol solid state forms |
| EP2249838A4 (en) * | 2008-02-05 | 2012-05-02 | Harbor Biosciences Inc | PHARMACEUTICAL FORMS IN SOLID STATE |
| JP2011527986A (ja) | 2008-04-03 | 2011-11-10 | ハーバー バイオサイエンシーズ，インコーポレイテッド | 医薬の固体状態形態 |
| EP2172190A1 (en) * | 2008-10-02 | 2010-04-07 | Laboratorios Liconsa, S.A. | Inhalable particles comprising tiotropium |
| US10987361B2 (en) | 2010-02-08 | 2021-04-27 | Shenzhen Evergreen Therapeutics Co., Ltd. | Treating auto-immune and auto-inflammatory diseases |
| US10993879B2 (en) | 2010-02-08 | 2021-05-04 | Shenzhen Evergreen Therapeutics Co., Ltd. | Pulmonary delivery of progestogen |
| EP2533799B8 (en) * | 2010-02-08 | 2019-12-25 | Shenzhen Evergreen Therapeutics Co., Ltd. | Methods for the use of progestogen as a glucocorticoid sensitizer |
| ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| CN102793929B (zh) * | 2012-09-07 | 2013-12-11 | 上海奥科达生物医药科技有限公司 | 一种制备稳定非晶态药物制剂的方法 |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US20200129438A1 (en) * | 2018-10-31 | 2020-04-30 | Edenbridge Pharmaceuticals, LLC | Finished pharmaceutical dosage form comprising a low dose/high potency active pharmaceutical ingredient and one or more excipients |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2648700A (en) * | 1946-11-02 | 1953-08-11 | Searle & Co | 2-methyl-2,7-dihydroxy-octahydrophenanthrene-1-propionic acid and derivatives thereof |
| US2636042A (en) * | 1949-07-08 | 1953-04-21 | S B Penick And Company | Water-soluble hormone compounds |
| US2642427A (en) * | 1951-08-01 | 1953-06-16 | Abbott Lab | Piperazine salts of cyclopentanopolyhydrophenanthrene-3-monosulfates |
| US2666066A (en) * | 1951-09-28 | 1954-01-12 | Abbott Lab | Ethylenediamine salts of cyclopen-tanopolyhydrophenanthrene-3-monosulfates |
| US3032469A (en) * | 1958-05-02 | 1962-05-01 | Charles E Frosst & Company | Long acting steroid compounds |
| US3568828A (en) * | 1967-03-01 | 1971-03-09 | Squibb & Sons Inc | Modified sequential oral contraceptive |
| US3691212A (en) * | 1970-04-24 | 1972-09-12 | British Drug Houses Ltd | 17alpha-(1',3'-alkadiynyl)-17beta-acyloxy(17beta-aroyloxy) steroids |
| US4046874A (en) * | 1974-02-13 | 1977-09-06 | Mead Johnson & Company | Soapless shave composition |
| US4511551A (en) * | 1982-11-18 | 1985-04-16 | Unique Technologies, Incorporated | Method and composition for the detection of a precancerous or leukemic condition in mammals |
| US4544554A (en) * | 1983-09-26 | 1985-10-01 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| US4616006A (en) * | 1983-09-26 | 1986-10-07 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| US4785103A (en) * | 1985-03-07 | 1988-11-15 | Teikoku Hormone Mfg. Co., Ltd. | 2-oxa- or -aza-pregnane compounds |
| US4906169A (en) * | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| US5407928A (en) * | 1990-08-15 | 1995-04-18 | Schering Aktiengesellschaft | 11β-aryl-gona-4,9-dien-3-ones |
| US5344392A (en) * | 1990-09-28 | 1994-09-06 | Baxter International Inc. | Method and apparatus for preparation of solutions from concentrates |
| FR2668945B1 (fr) * | 1990-11-12 | 1993-02-19 | Theramex | Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus. |
| IE67345B1 (en) * | 1991-03-12 | 1996-03-20 | Akzo Nv | Low dose dry pharmaceutical preparations |
| DK0542364T3 (da) * | 1991-11-13 | 1996-03-11 | Glaxo Canada | Anordning til reguleret frigivelse |
| US5395627A (en) * | 1992-09-04 | 1995-03-07 | Akzo N.V. | Pharmaceutical granulate |
| DE4229820C2 (de) * | 1992-09-07 | 1998-12-03 | Jenapharm Gmbh | Pharmazeutische Zubereitung auf Gestagen-Basis |
| IT1270831B (it) * | 1993-09-17 | 1997-05-13 | Romano Deghenghi | Composizioni farmaceutiche orali effervescenti contenenti estrone |
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| DE4429374C1 (de) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
| AR004178A1 (es) | 1995-07-29 | 1998-11-04 | Smithkline Beecham Plc | Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma. |
| DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| EP0956024B1 (en) * | 1996-07-26 | 2004-07-21 | Wyeth | Monophasic oral contraceptive method and kit comprising a combination of progestin and estrogen |
| US5858405A (en) * | 1996-07-26 | 1999-01-12 | American Home Products Corporation | Oral contraceptive |
| US6495532B1 (en) * | 1997-03-19 | 2002-12-17 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
| EP2002839A1 (en) * | 1998-04-17 | 2008-12-17 | Ortho McNeil Pharmaceutical, Inc. | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| DE19906152B4 (de) * | 1999-02-10 | 2005-02-10 | Jenapharm Gmbh & Co. Kg | Wirkstoffhaltige Laminate für Transdermalsysteme |
| US6667050B1 (en) * | 1999-04-06 | 2003-12-23 | Galen (Chemicals) Limited | Chewable oral contraceptive |
| ES2327538T3 (es) * | 2000-12-14 | 2009-10-30 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Proceso para preparar productos de hormona esteroidea que comprenden un agente estabilizante en forma no cristalina. |
-
2001
- 2001-12-13 ES ES05076805T patent/ES2327538T3/es not_active Expired - Lifetime
- 2001-12-13 US US10/022,138 patent/US7867990B2/en not_active Expired - Lifetime
- 2001-12-13 NZ NZ526517A patent/NZ526517A/en not_active IP Right Cessation
- 2001-12-13 DE DE60139087T patent/DE60139087D1/de not_active Expired - Lifetime
- 2001-12-13 EP EP05076805A patent/EP1591121B1/en not_active Expired - Lifetime
- 2001-12-13 ES ES01996273T patent/ES2253451T3/es not_active Expired - Lifetime
- 2001-12-13 DK DK01996273T patent/DK1361881T3/da active
- 2001-12-13 AT AT01996273T patent/ATE307591T1/de active
- 2001-12-13 AT AT05076805T patent/ATE434439T1/de active
- 2001-12-13 DK DK05076805T patent/DK1591121T3/da active
- 2001-12-13 EP EP01996273A patent/EP1361881B1/en not_active Expired - Lifetime
- 2001-12-13 AU AU2002227421A patent/AU2002227421B2/en not_active Expired
- 2001-12-13 KR KR1020037007977A patent/KR100899032B1/ko active IP Right Grant
- 2001-12-13 RS YUP-479/03A patent/RS50414B/sr unknown
- 2001-12-13 CZ CZ2003-1896A patent/CZ306435B6/cs not_active IP Right Cessation
- 2001-12-13 ME MEP-2008-488A patent/ME00339B/me unknown
- 2001-12-13 HU HU0400646A patent/HU230400B1/hu unknown
- 2001-12-13 BR BRPI0116793A patent/BRPI0116793B8/pt not_active IP Right Cessation
- 2001-12-13 CA CA2431521A patent/CA2431521E/en not_active Expired - Fee Related
- 2001-12-13 SK SK880-2003A patent/SK288222B6/sk not_active IP Right Cessation
- 2001-12-13 PT PT05076805T patent/PT1591121E/pt unknown
- 2001-12-13 IL IL15642301A patent/IL156423A0/xx unknown
- 2001-12-13 RU RU2003121240/15A patent/RU2286155C2/ru active
- 2001-12-13 CN CNB018225578A patent/CN1290507C/zh not_active Expired - Lifetime
- 2001-12-13 DE DE60114467T patent/DE60114467T2/de not_active Expired - Lifetime
- 2001-12-13 EE EEP200300229A patent/EE05358B1/xx unknown
- 2001-12-13 MX MXPA03005339A patent/MXPA03005339A/es active IP Right Grant
- 2001-12-13 UA UA2003065552A patent/UA77404C2/uk unknown
- 2001-12-13 AU AU2742102A patent/AU2742102A/xx active Pending
- 2001-12-13 WO PCT/US2001/048862 patent/WO2002047693A2/en not_active Application Discontinuation
-
2003
- 2003-06-12 IL IL156423A patent/IL156423A/en active IP Right Grant
- 2003-06-13 NO NO20032708A patent/NO334341B1/no not_active IP Right Cessation
- 2003-06-13 EC EC2003004654A patent/ECSP034654A/es unknown
- 2003-07-01 BG BG107958A patent/BG66178B1/bg unknown
- 2003-07-10 ZA ZA200305342A patent/ZA200305342B/en unknown
- 2003-07-14 CR CR7022A patent/CR7022A/es not_active Application Discontinuation
-
2004
- 2004-01-08 HK HK04100131A patent/HK1057174A1/xx not_active IP Right Cessation
-
2006
- 2006-02-09 HK HK06103511.8A patent/HK1083457A1/xx not_active IP Right Cessation
-
2009
- 2009-09-24 CY CY20091101002T patent/CY1109404T1/el unknown
-
2010
- 2010-11-02 US US12/917,519 patent/US20110046099A1/en not_active Abandoned
- 2010-11-02 US US12/917,514 patent/US20110046095A1/en not_active Abandoned
-
2013
- 2013-10-04 NO NO20131334A patent/NO20131334L/no not_active Application Discontinuation
-
2014
- 2014-06-26 US US14/315,738 patent/US20140309204A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003121240A (ru) | Препараты стероидного гормона и способы их получения | |
| EP1898953B1 (en) | Quadraphasic continuous graduated estrogen contraceptive | |
| KR100388932B1 (ko) | 물을결합시킬수있는부형제를포함하는고형약학조성물 | |
| JP3474210B2 (ja) | 低用量乾燥医薬製剤 | |
| JP3667778B2 (ja) | スフェロイド製剤 | |
| KR890004723A (ko) | 호르몬 제제 및 이의 제조방법 | |
| KR880701553A (ko) | 폐경기 전의 여성용 혼합 투약형 | |
| EP1488794A2 (en) | Methods of contraception | |
| HUE025147T2 (hu) | Lassú hatóanyag-leadású ösztradiol-progeszteron készítmény | |
| JPH10505846A (ja) | 湿式粒状化による投与単位体を製造する方法 | |
| KR950013752B1 (ko) | 분무 건조된 아세트아미노펜의 치료용 분말, 이의 제조방법 및 이를 함유하는 약제학적 제형 | |
| CA1082598A (en) | Solid steroid composition and process for preparation | |
| US5478571A (en) | Process for the preparation of substantially alcohol free pharmaceutical compositions | |
| JPS62205024A (ja) | エストロゲン欠乏症治療用組成物 | |
| EP0735862B1 (en) | Method for dry blend compression of medicaments | |
| JP2001523639A (ja) | プロゲストゲン−抗プロゲストゲンレジメン | |
| WO2018106914A1 (en) | Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent | |
| KR20010110807A (ko) | 조합 치료에서의 항프로게스타겐의 용도 |